Efruxifermin, a long-acting Fc-FGF21 analog that directly inhibits hepatic stress and collagen deposition, has been clinically reported to significantly ameliorate hepatic fibrosis and steatosis (Harrison et al., 2024a). Here, FGF21 is linked to Hepatic fibrosis.